<?xml version="1.0" encoding="UTF-8"?>
<p>AKT inhibitors have been studied as anticancer treatments for nearly two decades, resulting in the development of a number of compounds currently undergoing clinical trials [
 <xref rid="ppat.1006835.ref021" ref-type="bibr">21</xref>]. MK-2206 is a diphenylquinoxaline analogue that inhibits AKT by locking the kinase in a closed conformation and it has been tested alone or in combination against several malignancies [
 <xref rid="ppat.1006835.ref022" ref-type="bibr">22</xref>,
 <xref rid="ppat.1006835.ref023" ref-type="bibr">23</xref>]. Treatment of differentiated SH-SY5Y with MK-2206 caused a reduced release of infectious virions even more striking than Wortmannin (~84% vs. ~63%, respectively) (
 <bold>
  <xref ref-type="fig" rid="ppat.1006835.g004">Fig 4F</xref>
 </bold>). As for Wortmannin and LY294002, we observed an even more dramatic inhibition in rat primary neurons (~2 logs, 
 <bold>
  <xref ref-type="fig" rid="ppat.1006835.g004">Fig 4G</xref>
 </bold>). Cell viability following MK-2206 treatment is shown in 
 <bold>
  <xref ref-type="supplementary-material" rid="ppat.1006835.s004">S4H Fig</xref>
 </bold>.
</p>
